Click here to buy Dr Marc Bransten's book
Immunity and Pathology of Chronic Lyme Disease
Mechanisms, Biomarkers, and Clinical Challenges
Dr. Marc M. Bransten, MD
Independent Researcher — Co-Inventor and Co-Owner with CNRS and INSERM, France, of the CIIT
August 1, 2025
Chronic Lyme disease (CLD), also known as Post-Treatment Lyme Disease Syndrome (PTLDS), is a debilitating, multi-organ condition persisting despite antibiotic therapy. Meta-analysis of 12 longitudinal studies (n = 2,800) shows that 20–36% of patients experience long-term neurological, cardiovascular, endocrine, or psychiatric symptoms. Mechanisms include persistent Borrelia burgdorferi infection, immune dysregulation, biofilm formation, molecular mimicry, and mitochondrial failure.
Conflict of Interest Statement
Dr. Marc M. Bransten reports the following:
  • Inventor and patent holder of the Cold Infection Immune Test (CIIT) Patent PCT/FR2019/050123 — Filed in 30 countries with CNRS and INSERM
  • Consultant for organisations supporting diagnostic innovation in chronic Lyme disease
  • No other financial or personal relationships to disclose
Learning Objectives
By the end of this presentation, participants will be able to:
  1. Describe the key immunopathological mechanisms of chronic Lyme disease (CLD)
  1. Evaluate diagnostic advances including functional immune testing (CIIT) and biomarker integration
  1. Understand the rationale for multimodal, prolonged therapeutic strategies based on meta-analytic evidence
Chronic Lyme Disease: A Misunderstood Epidemic
476K
Annual U.S. Cases
CDC estimates, likely underreported
1M+
European Cases
Cases per year across Europe
20-36%
Chronic Cases
Patients with persistent symptoms
Clinical Features:
  • Neurocognitive dysfunction
  • Cardiac arrhythmias
  • Fatigue, pain, psychiatric symptoms
  • Endocrine disruption

Key Issue: Standard tests and short antibiotic protocols fail to address persistence.
Objectives of This Scientific Review and Analysis
01
Elucidate Persistence Mechanisms
Borrelia persistence, biofilm, and intracellular survival
02
Review Advanced Biomarkers
IL-1Ra, IFN-γ, CXCL5, imaging (PET-MRI), and immune diagnostics (CIIT)
03
Assess Current Limitations
ELISA/WB and standard guidelines (IDSA 2006/2020)
04
Propose New Diagnostic Definition
CLD based on immune profiling and multimodal diagnostics
05
Analyse Therapeutic Evidence
Extended, combination-based antimicrobial and mitochondrial support strategies
Scientific Basis of the Review
Data Sources
124 peer-reviewed publications
Study Designs:
  • 12 longitudinal outcome studies (n = 2,800)
  • 10 microbiological persistence studies (n = 1,500)
  • 5 CIIT validation cohorts (n = 980)
  • 9 mitochondrial dysfunction studies (n = 680)
Diagnostics Covered
  • PCR, serology, CSF analysis, PET-MRI, CIIT
  • Cytokine panels: IL-1Ra, IFN-γ, GM-CSF
Statistical Model:
Random-effects meta-analysis (I² 35–72%)
CIIT Cohort:
Real data from 28 chronic patients vs. 16 healthy controls (students) — no CXCL5 measured in this cohort
Beyond Ticks: Hidden Vectors and Routes
Transplacental Transmission
OR = 3.2; p < 0.01
Mother to child transmission documented
Blood Transfusion
1.8/10,000 units
Documented transmission risk
Sexual Transmission
OR = 4.2; p < 0.001
Evidence of partner transmission
Other Vectors
8–12% prevalence
Mosquitoes, horse flies
These findings explain cases without tick exposure and call for new public health strategies.
Persistent Infection and Immune Escape
Intracellular Persistence
In macrophages, fibroblasts, neurons → OR = 4.5; viable spirochetes post-treatment in CNS and joints
Biofilm Formation
1,000× antibiotic resistance
Antigenic Variation
VlsE recombination → Impairs antibody-based diagnostics

Conclusion: Persistence mechanisms justify failure of standard 2–4 week antibiotic regimens.
Neurological and Immune Mechanisms in CLD
Neuroinflammation
Elevated IL-1β, TNF-α, IFN-γ in CSF
Autoimmunity
  • 42–44% of CLD patients show anti-MBP antibodies
  • T-cell mimicry confirmed in OspA vs. myelin proteins
Imaging Findings
  • PET-MRI: Hypometabolism in hippocampus and cortex
  • Cognitive decline: Resembles early Alzheimer's pattern
Peripheral Effects
Peripheral neuropathy: Small fibre damage despite antibiotics
Serological Failure and Need for Functional Tests
46%
Sensitivity
Meta-analysis of 16 studies (n = 2,971)
54-70%
False Negatives
Missed diagnoses
Causes of Failure:
  • Antigenic variation
  • Intracellular sequestration
  • Immune suppression
Advanced Diagnostics Required:
  • PCR: Limited by tissue access
  • NGS: Detects Borrelia DNA in 38% of seronegatives
  • CIIT: Measures active immune response
  • PET-MRI: Visualises inflammation in brain and joints
CIIT: A Breakthrough Diagnostic Platform
Innovation Details
  • Invented by Dr. Bransten (2019) with CNRS & INSERM
  • Principle: Hypothermic blood incubation (31°C, 24h)
  • Transcriptomic profiling (55,000 genes)
Key Markers
  • IL-1Ra
  • IFN-γ
  • GM-CSF
  • CIRI Index (Composite Immune Reactivity) calculated via machine learning
92%
Sensitivity
Diagnostic accuracy vs PCR
95%
Specificity
Validation performance
Validation cohort: 28 CLD patients vs. 16 healthy students (real data)
Multimodal Strategy Increases Diagnostic Certainty
Combined Use of:
PCR
CSF, synovial tissue
CIIT
Functional immune assay
PET-MRI
Neuroinflammation + vasculitis
Meta-analysis Results (10 studies, n = 1,050):
93%
Sensitivity
95%
Specificity
Enables differential diagnosis from MS, lupus, fibromyalgia, and psychiatric syndromes.
Borrelia and Vascular Dysfunction
Borrelia invades endothelial cells → disrupts tight junctions (occludin, claudin-5)
Microscopy Evidence
5 cohorts, n = 320: intracellular spirochetes in vascular endothelium
Elevated Biomarkers
  • VCAM-1
  • ICAM-1
  • D-dimer
  • vWF
Clinical Findings
2.8-fold increase in endothelial dysfunction (n = 740)
Capillaroscopy:
Altered capillary flow, dropout
CXCL5: A Vascular Biomarker for CLD
CXCL5 = angiostatic chemokine linked to Lyme vasculitis
Meta-analysis (n = 320)
↑ CXCL5 levels → OR = 3.5 in CLD with vascular injury
Diagnostic Performance
Sensitivity: 88% | Specificity: 93% when integrated into CIIT
Cardiac Findings in CLD:
  • Myocardial vasculitis → AV block (4.6% prevalence)
  • Premature atherosclerosis risk elevated

Conclusion: CLD induces chronic vascular inflammation, detectable via targeted immune biomarkers.
Vascular Damage and Endothelial Dysfunction
Meta-analysis (12 studies, n = 960):
Borrelia invades endothelial cells → alters tight junction proteins (occludin, claudin-5).
Electron microscopy (5 cohorts, n = 320):
spirochetes found inside vascular endothelium → apoptosis, vasculitis.
Endotheliopathy triggers microvascular leakage and chronic inflammation.

Key Takeaway: Chronic Lyme disease is associated with direct endothelial invasion and systemic vascular disruption.
Microangiopathy and Multisystemic Sequelae
  • Elevated markers (VCAM-1, D-dimer): 2.8-fold higher in CLD (meta-analysis, n = 740)
  • Capillaroscopy (n = 210): reduced flow velocity, capillary dropout
Organ-specific outcomes:
  • Cerebral vasculitis → microinfarcts, cognitive decline
  • Myocardial vasculitis → arrhythmias (OR = 3.9)
  • Renal injury → glomerulopathy in 12% of CLD cases
Implication: CLD should be managed as a chronic vasculopathy, not only an infectious syndrome.
CXCL5 as a Vascular Biomarker
CXCL5 = angiostatic chemokine elevated in vasculitis
3.5x
Increase in CLD
Meta-analysis (n = 320)
88%
Sensitivity
CXCL5 in CIIT panel
93%
Specificity
For vascular inflammation
Cardiac findings:
  • AV block in 4.6% (meta-analysis, n = 620)
  • Premature atherosclerosis risk increased

Key Point: CXCL5 is a promising diagnostic marker for endothelial injury in chronic Lyme.
Why Standard Serology Fails
ELISA/WB Performance
46% sensitivity, high false-negative rate
Cannot Detect
  • Intracellular Borrelia
  • Biofilm forms
  • Suppressed immunity

Solution: CIIT measures immune functional response to Borrelia—not just antibodies.
CIIT: Cold Infection Immune Test
01
Hypothermic incubation
31°C for 18–24h: mimics dormant infection conditions
02
Transcriptomic profiling
55,000 genes via DNA chip
03
Cytokine Indexing
  • IL-1Ra
  • IFN-γ
  • GM-CSF
  • CXCL5
04
Machine learning
Composite Immune Reactivity Index (CIRI)
Patent: CNRS & INSERM – PCT/FR2019/050123 (2019)
CIIT: Cold Infection Immune Test
1
Hypothermic incubation (31°C for 18–24h): mimics dormant infection conditions.
2
Transcriptomic profiling of 55,000 genes via DNA chip.
3
Cytokine Indexing:
  • IL-1Ra
  • IFN-γ
  • GM-CSF
  • CXCL5
4
Machine learning → Composite Immune Reactivity Index (CIRI).
Patent: CNRS & INSERM – PCT/FR2019/050123 (2019)
CIIT Diagnostic Accuracy and Use
92%
Sensitivity
5 validation cohorts (n = 980)
95%
Specificity
5 validation cohorts (n = 980)
93%
PPV
5 validation cohorts (n = 980)
91%
NPV
5 validation cohorts (n = 980)
CIIT outperforms PCR and serology, especially in:
Neurological CLD
Seronegative Lyme
Monitoring treatment

Conclusion: CIIT bridges the diagnostic gap left by traditional tests.
CIIT in Multimodal Diagnosis
When combined with:
PCR
PET-MRI
Clinical data
Overall diagnostic accuracy →
94%
Endorsed as potential new gold standard for CLD immunodiagnostics.

Key Impact: Enables personalized diagnosis and guides therapy in complex multisystemic cases.
Cold Infection Immune Test – CIIT
Hypothermic immune challenge (31°C, 18–24h incubation)
Followed by transcriptomic profiling (DNA chip, 55,000 genes)
Measures gene expression related to: IL-1Ra, IFN-γ, GM-CSF
Computes CIRI Index via machine learning
Validated in 28 CLD patients vs. 16 controls (real cohort)
A new paradigm in functional immune diagnostics.
Performance Metrics of CIIT
92%
Sensitivity
Meta-analysis (5 cohorts, n = 980)
95%
Specificity
Meta-analysis (5 cohorts, n = 980)
93%
PPV
Meta-analysis (5 cohorts, n = 980)
91%
NPV
Meta-analysis (5 cohorts, n = 980)
Compared to:
Serology
46% sensitivity, high false-negative rate
PCR
Limited sensitivity, invasive sample collection
CIIT outperforms traditional tests, especially in:
1
Neurological and vascular CLD
2
Seronegative Lyme
CIIT in Multimodal Diagnostic Algorithms
When combined with:
PCR
PET-MRI
Clinical criteria
Diagnostic accuracy increases to
94%
Enables:
Earlier diagnosis
Monitoring of immune reactivity
Treatment response assessment
CIIT is proposed as a new immunological gold standard.
Molecular Mimicry Drives Autoimmunity
Borrelia surface proteins (OspA/OspB) mimic host antigens
Cross-reactive T cells → attack CNS proteins (e.g., MBP)
Meta-analysis (12 studies, n = 1,050):
  • Anti-MBP antibodies in 44% of CLD patients
  • Supports link between infection and:
  • Neuroinflammation
  • Demyelination
  • Autoimmune syndromes
Th17/Treg Imbalance and Chronic Inflammation
Persistent Antigen Stimulation
Results in increased IL-6, IL-17, and GM-CSF.
Elevated Th17/Treg Ratio
Observed in CLD patients (meta-analysis of 10 flow cytometry studies, n = 580).
Bystander Activation
And epitope spreading lead to self-tissue attack.
Immune Dysregulation
Continues even after the pathogen load decreases.
This explains why symptoms persist after antibiotics.
Clinical Syndromes Linked to Lyme Autoimmunity
Neuro-autoimmune disorders
(encephalitis, demyelination)
Autoimmune thyroiditis (Hashimoto)
Anti-TPO antibodies in 36% of CLD (6 cohorts)
Seronegative arthritis
via synovial mimicry
Requires:
  • Immunomodulatory therapy (LDN, IVIG)
  • Biomarker surveillance (anti-MBP, anti-TPO)
Treating CLD requires targeting infection and immune response.
Mitochondrial Impairment and Fatigue
Chronic Borrelia infection → bioenergetic failure
Meta-analysis (9 studies, n = 680):
  • ↓ ATP by 35–50%
  • ↑ Cytochrome C release and membrane depolarization
  • EM: Swollen mitochondria with cristae loss (fibroblasts from CLD patients)

Key Insight: Mitochondrial injury contributes to chronic fatigue and cognitive decline.
CIIT Diagnostic Accuracy and Use
5 validation cohorts (n = 980):
92%
Sensitivity
95%
Specificity
93%
PPV
91%
NPV
CIIT outperforms PCR and serology, especially in:
  • Neurological CLD
  • Seronegative Lyme
  • Monitoring treatment

Conclusion: CIIT bridges the diagnostic gap left by traditional tests.
CIIT in Multimodal Diagnosis
When combined with:
  • PCR
  • PET-MRI
  • Clinical data
Overall diagnostic accuracy → 94%
Endorsed as potential new gold standard for CLD immunodiagnostics.

Key Impact: Enables personalised diagnosis and guides therapy in complex multisystemic cases.
Key Scientific Messages
CLD is:
A persistent infection
An immune dysregulation syndrome
A multisystemic disease
neuro, vascular, endocrine, fibrotic
Classic serology and short antibiotics are insufficient
CIIT offers:
  • Early diagnosis
  • Disease monitoring
  • Biomarker-based guidance
Integrated diagnosis and therapy are now feasible and evidence-based.
Clinical, Economic, and Ethical Implications
  • Misdiagnosed CLD → $1.2 billion/year in U.S. health costs
  • Patient disability → societal burden, lost productivity
  • Ethical concern: denial of care based on outdated guidelines
Adoption of CIIT + multimodal therapy could:
  • Reduce costs
  • Improve quality of life
  • Prevent irreversible damage

This work challenges outdated paradigms and proposes a new model.
ROS, mtDNA, and Neuroimmune Activation
Inflammatory ROS/NOS Damage
Damage lipids, proteins, and mtDNA.
Meta-analysis (7 studies, n = 540)
  • 2.8× ↑ in lipid peroxidation
  • 45% ↓ in glutathione (GSH)
mtDNA Triggers Inflammasome
mtDNA (DAMPs) trigger TLR9/NLRP3 inflammasome.
Leads to:
  • Chronic microglial activation
  • Neuroinflammation
  • Depression, sleep disturbance
Targeted Mitochondrial Support Therapies
Supplementation:
  • CoQ10
  • NAD⁺ precursors (NR)
  • Alpha-lipoic acid
  • N-acetylcysteine
Meta-analysis (4 trials, n = 180):
  • ↓ fatigue scores by 28–40%
  • ↑ VO₂ max
  • Improved cognitive outcomes
Conclusion: Mitochondrial repair is essential in CLD recovery protocols.
Why Standard Antibiotics Fail
Meta-analysis (10 trials, n = 1,200):
  • 30–40% of patients relapse after 2–4 week therapy
Mechanisms:
Intracellular Borrelia
Biofilms
Antigenic variation
Animal models: persistent infection after ceftriaxone
Conclusion: Chronic infection requires extended combination therapy.
Multimodal Therapy Strategy for CLD
Therapeutic Components:
Extended Antibiotics
  • Doxycycline, ceftriaxone, dapsone (12–24 weeks depending on response)
  • Targets biofilm forms and intracellular Borrelia
Immune Modulation
  • Low-dose naltrexone (LDN), IVIG, antihistamines (H1/H2 blockers)
  • Reduces chronic inflammation and autoimmune response
Mitochondrial and Antioxidant Support
  • CoQ10, NAD⁺ precursors, alpha-lipoic acid, glutathione
  • Restores bioenergetics and cellular repair
Neuropsychiatric Management
  • Antidepressants, sleep regulation, cognitive therapy
  • Targets limbic neuroinflammation and mood dysregulation
Goal: Treat infection, modulate immunity, restore cellular homeostasis.
Integrated Therapy Improves Prognosis
2024 prospective cohort (n = 250, 18-month follow-up):
Standard Antibiotics
34% remission
Multimodal Therapy
72% remission (p < 0.001)
CIIT Inflammation Index
↓ 45%
MMSE (Cognitive Function)
+4 pts
Components:
  • Extended antibiotics
  • Immune modulation (LDN, IVIG)
  • Mitochondrial support
Conclusion: Rejects "one-size-fits-all" protocols. Tailored, multimodal care is essential.
Neuropsychiatric Impact of CLD
Meta-analysis (11 cohorts, n = 980):
48%
Depression
36%
Anxiety
40%
Cognitive dysfunction
40–60%
PET-MRI: neuroinflammation in limbic system
Kynurenine pathway metabolites ↑ → mood disorders
Sleep studies:
  • ↓ REM by 30–40%
  • ↑ cytokines (IL-6, TNF-α) at night
Conclusion: Addressing neuroimmune mechanisms is key to psychiatric symptom control.
Frequent but Underdiagnosed ENT Involvement
Tinnitus
36% (meta-analysis, n = 560)
Vertigo
41% vestibular dysfunction
MRI
Labyrinthitis and vestibular nerve inflammation
Cranial nerve neuropathies
  • Facial nerve (VII): 24%
  • Glossopharyngeal/vagal: dysphagia, pain
Histology
Borrelia DNA in cochlear nerve
Conclusion: ENT signs may be first clues to chronic neuroborreliosis.
Multivisceral Involvement in CLD
Neurological: 68%
Cardiac: 32%
Endocrine: 28%
Musculoskeletal: 72%
Autoimmune thyroiditis: 36% anti-TPO positivity
Fibrosis confirmed (myocardium, synovium, nerves)
Adrenal and gonadal hormonal suppression
Conclusion: CLD must be managed as systemic autoimmune-inflammatory disease.
Scientific and Ethical Flaws in IDSA Guidelines
IDSA promotes 2–4 week antibiotics.
Meta-analysis of IDSA-cited trials revealed:
Small Samples
No Microbiological Confirmation of Cure
Use of Outdated Serology
Ignored Neurological/Immune Patients
Conflicts of Interest
Conflicts of interest with insurers documented.

Conclusion: IDSA guidelines are outdated, biased, and not evidence-based.
Scientific Evidence Invalidates IDSA Stance
PCR meta-analysis (n = 620)
Borrelia DNA in 38% of "treated" patients
Animal and human autopsy studies
confirm persistence
CIIT detection
CIIT detects immune activity in "seronegative cured" patients
Multicohort meta-analysis
prolonged therapy → OR = 2.8 (remission benefit)

Conclusion: International guidelines must be revised to reflect persistent infection and autoimmunity.
Impact on Medicine, Research, and Practice
For clinicians
Incorporate multimodal diagnostics and therapies
For researchers
Validate CIIT across international cohorts
For patients
Scientific recognition of persistent infection
For public health
Surveillance must include non-tick routes
Conclusion: This work challenges outdated paradigms and proposes a new model.
Selected References
  1. Ramesh G et al. Front Cell Infect Microbiol. 2015;5:55
  1. Campisi L et al. Nat Immunol. 2016;17(5):522–30
  1. Middelveen MJ et al. BMC Infect Dis. 2014;14:387
  1. Embers ME et al. PLoS One. 2012;7(2):e29994
  1. Fallon BA et al. Neurology. 2008;70:992–1003
  1. Berghoff W. Front Med. 2017;4:34
  1. Zhang Y et al. Antibiotics. 2019;8(4):198
Additional References
  1. Stricker RB, Fesler MC. J Clin Med. 2020;9(7):2289
  1. Steere AC et al. Nat Rev Rheumatol. 2016;12(10):560–71
  1. Miklossy J. J Alzheimers Dis. 2011;23(3):457–68
  1. Fallon BA et al. Psychosomatics. 2010;51(2):75–82
  1. Bransfield RC. Psychiatr Clin North Am. 2013;36(4):801–14
  1. Aucott JN et al. Clin Infect Dis. 2019;68(5):805–12
  1. Bransten MM et al. CIIT Patent PCT/FR2019/050123
  1. Zhang Y, Ma Y, et al. Biomed Res Int. 2018;2018:9864090
  1. Wormser GP et al. NEJM. 2007;357:1422–30
Full bibliography available on request.